# Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

> **NCT01374906** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 150 (actual)

## Conditions studied

- Cushing's Disease

## Interventions

- **DRUG:** pasireotide LAR
- **DRUG:** SOM230 LAR 30 mg
- **DRUG:** SOM230 LAR 10 mg

## Key facts

- **NCT ID:** NCT01374906
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-04
- **Primary completion:** 2016-12-21
- **Final completion:** 2016-12-21
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2018-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01374906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01374906, "Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01374906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*